Loading clinical trials...
Loading clinical trials...
A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Conditions
Interventions
UCB1381
Placebo
Locations
16
United States
Up0110 125
Beverly Hills, California, United States
Up0110 101
Glendale, California, United States
Up0110 116
Los Angeles, California, United States
Up0110 121
Northridge, California, United States
Up0110 126
Tustin, California, United States
Up0110 127
Valencia, California, United States
Start Date
March 7, 2022
Primary Completion Date
July 17, 2025
Completion Date
September 19, 2025
Last Updated
October 20, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions